Fludarabine
- Generic Name
- Fludarabine
- Brand Names
- Fludara
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12FN5O4
- CAS Number
- 21679-14-1
- Unique Ingredient Identifier
- P2K93U8740
- Background
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
- Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
- Associated Conditions
- B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaRecurrent Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06777979
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
- Conditions
- MesotheliomaNeoplasmsStomach NeoplasmsPancreatic NeoplasmsOvarian NeoplasmsLung NeoplasmsThymus NeoplasmsColonic Neoplasms
- Interventions
- Device: mesothelin expression testingBiological: TNhYP217 CAR T Cells
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT06885697
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
- Conditions
- B-Cell Non-Hodgkin LymphomaB-cell Acute Lymphoblastic Leukemia
- Interventions
- Drug: DuoCAR20.19.22-D95Drug: Cyclophosphamide (Conditional therapy)
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 54
- Registration Number
- NCT06879340
- Locations
- 🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- Drug: Autologous Anti-CD83 CAR T-cellsProcedure: Biospecimen CollectionProcedure: Chest RadiographyProcedure: Computed TomographyProcedure: EchocardiographyProcedure: LeukapheresisProcedure: Lumbar PunctureProcedure: Positron Emission TomographyOther: Questionnaire Administration
- First Posted Date
- 2025-03-12
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 26
- Registration Number
- NCT06871410
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Allo HSCT for High Risk Hemoglobinopathies
- Conditions
- Graft FailureSickle Cell DiseaseHemoglobinopathies
- Interventions
- Radiation: Total Body IrradiationBiological: Cell Infusion
- First Posted Date
- 2025-03-12
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 62
- Registration Number
- NCT06872333
- Locations
- 🇺🇸
Masonic Cancer Center, Minneapolis, Minnesota, United States
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
- Conditions
- Rhabdomyosarcoma
- Interventions
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT06865664
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT06847269
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
- Conditions
- Non Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06838832
CER-1236 in Patients With Acute Myeloid Leukemia (AML)
- Conditions
- AMLAcute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- CERo Therapeutics Holdings, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT06834282
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors
- Conditions
- Advanced Solid TumorsOvarian CancersPeritoneal (metastatic) Cancer
- Interventions
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Peking University
- Target Recruit Count
- 18
- Registration Number
- NCT06825455
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.